|The CSO of ExpreS2ion Biotech Holding and CEO of its joint-venture AdaptVac Willem "Wian" A. de Jongh, PhD speaks at the ISBiotech conference in US March 5-7 about the VLP-technology (Virus-like particles) and ExpreSion/AdpatVac's promising HER2-project in breast cancer. |
"HER2 Cancer Vaccine Optimization by Combining Drosophila S2
Insect Cell Manufacturing with a Novel VLP-Display Technology"
The goal is to reach a partner deal this year regarding the HER2-project specifically or the VLP-platform in general. That is most likely the biggest trigger in 2018 for the ExpreS2ion Biotech Holding stock. The market capital of ExpreS2ion is around USD 17.5 million and my belief is that a good deal could be worth a lot more, maybe 2-3 times current market capital or more.
The VLP technology could be a possible threat to and compete with producers of extremely expensive monoclonal antibodies (for example used in cancer against HER2, PD-L1, CTLA-4 etc and other diseases such as asthma IL-5) since the vaccines produced by the platform, via the body's own B-cells, can generate antibodies against, in principle, any antigen chosen for the VLP-vaccine (proved in mice for many different antigens ncbi.nlm.nih.gov
And combined with ExpreS2ion's own world leading complex protein production platform ExpreS2, the company should be able to produce the actual vaccines in house.
A rather unique feature of the VLP-technology is that it can direct the immune system against chosen self-proteins (such as HER2), so instead of administrating expensive monoclonal antibodies, the VLP-vaccine cause the human body's B-cells to produce natural antibodies at a low cost.
After the ongoing and soon ending rights issue, which has temporarily put a pressure down on the stock value, ExpreS2ion should have enough capital to reach their goals.